Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.

Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).